



The Antimicrobial Stewardship and Resistance Update

Biannual newsletter providing updates on news, reports, research, policies, and events related to antimicrobial stewardship and resistance in California.

Issue 6

Page

- 2. Interfacility Transfer Form
 - Barriers and Solutions
- 3. Electronic Solutions for Interfacility Communication
 - Using Interfacility Electronic Medical Record Access to Improve Stewardship
 - Examples of Hospitals Updating their Electronic Medical Record to Improve Transfers
 - Examples of Local Health Departments Facilitating Interfacility Notification of MDRO Status
- 5. Clinical and Laboratory Standards Institute (CLSI) Strengthens Recommendations for Carbapenemase Testing of Carbapenem-Resistant Enterobacterales
- 6. State Lab Announces New STAR-Carba Assay
- 6. CDPH Healthcare-Associated Infections Program Antimicrobial Stewardship Honor Roll Gold-Level Facility Spotlights
- 7. Updates



Improving Interfacility Communication

To prevent the spread of multidrug-resistant organisms (MDROs), the CDC recommends four key strategies (www.cdc.gov/healthcare-associatedinfections/php/preventing-mdros/mdro-preventionstrategies.html): 1) conducting education, 2) improving infection prevention and control (IPC) measures, 3) detecting colonized individuals, and 4) facilitating communication. This issue focuses on the fourth strategy, facilitating communication. Effective communication during patient transfers plays a pivotal role in improving patient safety and care coordination. Streamlining and standardizing the exchange of patient information—such as antimicrobial use and MDRO status—empowers receiving facilities to implement timely IPC and antimicrobial stewardship measures to optimize patient care.



Interfacility Transfer Form

According to California Health and Safety Code section 1262.5 (leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml? sec tionNum=1262.5.&lawCode=HSC), hospitals must provide a transfer summary including essential information related to the patient's care when transferring to a skilled nursing facility or intermediate care facility. However, interfacility communication is often challenging due to non-standardized transfer processes, limited provider time, competing provider priorities, and incompatible electronic medical record (EMR) systems between hospitals and skilled nursing facilities (SNFs). Interfacility transfer communication tools can streamline patient care by ensuring relevant information for IPC and antimicrobial stewardship is communicated in a standardized way.

Interfacility transfer communication tools can be physical forms sent with patients during the transfer process, such as the example in CDPH's Interfacility Transfer Communications Guide (www.cdph.ca. gov/Programs/CHCQ/ HAI/Pages/Interfacility Communication.aspx), or electronic forms built into the EMR. Electronic tools can be more efficient than paper forms, as

Patient Name (Last.	First):					
Date of Birth:	MRI	4:		Transfer Date:		
Receiving Facility N	lame (if known):					
Contact Name (option	onal):		Contact	t Phone (optiona	i):	
Sending Facility Na	me:					
Contact Name:			Contact	t Phone:		
PRECAUTIONS		Mbi		-1-		
Patient currently or	precautions?	If yes, check				_
□Yes □No				t 🗆 Droplet 🗅		Barrier
Skilled nursing faciliti acilities/hcp/prevent- with infection or colori unhealed wounds; Con ORGANISMS (Include Patient is NOT kn organisms requir Patient has MORK	mdro/PPE.html), ization with targer tact Precautions of copy of lab resultions from to be color ing precautions or other lab re	i.e., gown and glov ted multidrug-resi might be used for t alts with organism sized or infected (skip section)	e use for histant organi hese patien in IIO and an with any m	gh-contact care a sms (MDROs), ind ts in acute care s timicrobial susc nultidrug-resist	ctivities for r welling devic ettings. eptibilities.) ant or other	es or
acilities/hcp/prevent- with infection or coloni unhealed wounds; Con ORGANISMS (Include Patient is NOT kn organisms requir	mdro/PPE.html], zation with targer tact Precautions copy of lab resu- sown to be color ing precautions or other lab re- date) Or other (record	i.e., gown and glov ted multidrug-resi might be used for t sits with organism sized or infected (skip section) sults requiring p	e use for his stant organi these patien in ID and an with any in recautions ast date(s)	gh-contact care a sms (MDROs), ind ts in acute care s timicrobial susc sultidrug-resist (record organis	activities for n welling devic ettings. eptibilities.; ant or other m(s), specin nown)	es or
acilities/hcp/prevent- with infection or colon wheeled wounds; Cor ORGANISMS (Include Patient is NOI kn organisms requir Patient has MORK source, collection Exposed to MDRK	mdro/PPE.html] zation with targe tact Precautions; copy of lab resu cown to be color ing precautions O or other lab re idate) Or other (record Organism	i.e., gown and glov ted multidrug-resi might be used for t sits with organism sized or infected (skip section) sults requiring p	e use for his stant organishese patien in ID and an with any in recautions ast date(s)	gh-contact care a sms (MDROs), ind ts in acute care s timicrobial susc sultidrug-resist (record organis) of exposure if k	activities for r welling devic ettings. eptibilities. ant or other m(s), specin	es or
acilities/hcp/prevent- with infection or colon unhealed wounds; Con ORGANISMS (Include Patient is NOT k organisms requir Patient has MDR(source, collection Exposed to MDR(Candide ouris(C.	endro/PPE.html), zation with targe tact Precautions: copy of lab resu sown to be color ing precautions of or other lab re- idate) O/other (record Organism puris)	i.e., gown and glov ted multidrug-resi might be used for t sits with organism sized or infected (skip section) sults requiring p	e use for his stant organishese patien in ID and an with any in recautions ast date(s)	gh-contact care a sms (MOROs) ind ts in acute care s timicrobial susc nultidrug-resist (record organis of exposure if k arbapenemase)	activities for n welling devic ettings. eptibilities.; ant or other m(s), specin nown)	es or
acilities/hcg/prevent- with infection or colori unhealed wounds; Con- DROANISMS (Include Patient is NOI an organisms requir Patient has MDRX source, collection Exposed to MDRX Candida auris (C. Clostridiodes diff	endro/PPE.html) ization with target ization with target ization with target ization with target copy of lab resu copy of lab	i.e., gown and glow ted multidrug-resi might be used for a sits with organism sized or infected (skip section) sults requiring p organism(s) and l	e use for his stant organishese patien in ID and an with any in recautions ast date(s)	gh-contact care a sms (MOROs) ind ts in acute care s timicrobial susc nultidrug-resist (record organis of exposure if k arbapenemase)	activities for n welling devic ettings. eptibilities.; ant or other m(s), specin nown)	es or
acilities http://prevent- with infection or with infection or with infection or with infection or organisms require Patient is NOT kn organisms require Patient has MDRC source, collection Exposed to MDRC Costriction	emdro/PPE.html), ization with targe tact Precautions in copy of lab results on the color ing precautions of or other lab reduced on the color ing precautions of or other lab reduced of the color of th	i.e., gown and glove ted multidrug-resi might be used for t alts with organism sized or infected (skip section) sults requiring programism(s) and to the q. CRAB**)	e use for his stant organishese patien in ID and an with any in recautions ast date(s)	gh-contact care a sms (MOROs) ind ts in acute care s timicrobial susc nultidrug-resist (record organis of exposure if k arbapenemase)	activities for n welling devic ettings. eptibilities.; ant or other m(s), specin nown)	es or
acilities hepiprevent vitri infection or colori urbealed wounds; Coro MGANISMS (Included wounds; Coro GRANISMS (Included Corporations) or patient is NOI kn organisms required properties outree, coliection of Exposed to MDRC Condition of Condition outris (C. Clostricifolder diff. Actinet Observations) or Coro Condition outris (C. Clostricifolder diff. Actinet Observations) or Pseudomonose Pseudomonose	emdro/PPE home; tact Precautions i copy of lab resu copy	i.e., gown and glow ted multidrug-resi might be used for t sits with organism sized or infected (skip section) sulfs requiring p organism(s) and to tet (e.g., CRAB**) toterales (CRE**)	e use for his stant organistant organishese patien in IIO and an with any in recautions ast date(s)	gh-contact care a sms (MOROs) ind ts in acute care s timicrobial susc nultidrug-resist (record organis of exposure if k arbapenemase)	activities for n welling devic ettings. eptibilities.; ant or other m(s), specin nown)	es or
acilities hepipreventi infection or colori urbealed wounds; Coro MGANISHS (Include Wounds; Coro Omganishs (Coro Omganishs require Patient is NOT kn organisms require Patient has HORK osource, collection Exposed to MGRG	mdro/PPE.html; zation with targe tact Precautions i copy of lab resu ing precautions or other lab re idate) Or other lab re idate) Organism ouris) cole (C. diff) uitidrug-resistat istant Enterobas stant Enterobas ruglinosa, multidi	i.e., gown and glow ted multidrug-resi might be used for t afts with organism slized or infection) suffs requiring p organism(s) and I et (e.g., CRAB**) thereales (CRE**) rug-resistant (e.g.	re use for his stant organistant organisms in III and an with any m recautions ast date(s)	gh-contact care a sms (MOROs) ind ts in acute care s timicrobial susc nultidrug-resist (record organis of exposure if k arbapenemase)	activities for n welling devic ettings. eptibilities.; ant or other m(s), specin nown)	es or
acilities hepiprevent vitri infection or colori whealed wounds; Coro MGANISMS (Include Wounds; Coro Granisms require Patient has MDT kn organisms require Exposed to MDRC Candida auris (C. Cand	mdro/PPE html; zation with taxion with section to be color ing precautions of the properties of the pr	i.e., gown and glow the default of the superior of the might be used for to sits with organism sized or infected (skip section) sults requiring programism(s) and I organism(s) and I the g. CRAB**) the g. CRAB**) the g. CRAB**) as (ESBL) produced in the superior organism (s. g. cRAB**)	e use for his stant organistant organisms in ID and an with any m recautions C()	gh-contact care a sms (MOROs) ind ts in acute care s timicrobial susc nultidrug-resist (record organis of exposure if k arbapenemase)	activities for n welling devic ettings. eptibilities.; ant or other m(s), specin nown)	es or
acilities hepiprevent. Michael Service Servic	mdro/PPE.html; zazton with targe zazton verb targe zazton verb targe zazton verb zazton copy of lab res own to be color ing precautions of or other lab re date) Or other lab re date) Orother (record Organism suris) cole (C. diff) will idrug-resistar stant Enteroba- ruginosa, multid um beta-lactam ant Staphylocoo	i.e., gown and gloo- ted multidrug-resimight be used for t lifts with organism sized or infected ([skip section]) sufts requiring p organism(s) and i etc.g. CRAB**) cterales (CRE**) rug-resistant (e.g. ase (ESBL)-productus ourseus (IRSS)	e use for his stant organistant organisms in ID and an with any m recautions C()	gh-contact care a sms (MOROs), ind ts in acute care s timicrobial susc nultidrug-resist (record organis of exposure if k arbapenemase)	activities for n welling devic ettings. eptibilities.; ant or other m(s), specin nown)	es or
acilities hepipreventivis infection or colori with infection or colori with infection or colori presential colori patient is NOT kn organisms require. Patient has MDRs source, collection Condition our is CC. Closs	endro/PPE hersi, acadio with targe tact Precautions is copy of lab ress cown to be color into precautions of or other lab reductions. Or other lab reduction of or other lab reduction of other (record Organism souris) color (C. diff) utilidrup resistant action multidid um beta-lactam art Staphylococa stant Enterchoor art Staphylococa stant Enterchoor arts Staphylococa stant Enterchoor acts and Enterchoor	i.e., gown and glow ted multidrug-resimight be used for a dits with organisa issed or infected (skip section) sults requiring pro- organism(s) and li- merales (GRE**) merales (GRE**) asse (ESBL+produces coverus (PRS) cost (VRE)	re use for his stant organi hese patient organi hese patient or III and an with any mrecautions ast date(s)	gh-contact care a sms (MOROs), ind ts in acute care s timicrobial susc nultidrug-resist (record organis of exposure if k arbapenemase)	activities for n welling devic ettings. eptibilities.; ant or other m(s), specin nown)	es or
acilities hepiprevent vitri infection or colori wheeled wounds; Con ORGANISHS (Include Wounds; Con ORGANISHS (Include Con ORGANISHS)) Patient is NOT kn organisms required to the control of the control	endro/PPE hersi, acadio with targe tact Precautions is copy of lab ress cown to be color into precautions of or other lab reductions. Or other lab reduction of or other lab reduction of other (record Organism souris) color (C. diff) utilidrup resistant action multidid um beta-lactam art Staphylococa stant Enterchoor art Staphylococa stant Enterchoor arts Staphylococa stant Enterchoor acts and Enterchoor	i.e., gown and glow ted multidrug-resimight be used for a dits with organisa issed or infected (skip section) sults requiring pro- organism(s) and li- merales (GRE**) merales (GRE**) asse (ESBL+produces coverus (PRS) cost (VRE)	re use for his stant organi hese patient organi hese patient or III and an with any mrecautions ast date(s)	gh-contact care a sms (MOROs), ind ts in acute care s timicrobial susc nultidrug-resist (record organis of exposure if k arbapenemase)	activities for n welling devic ettings. eptibilities.; ant or other m(s), specin nown)	es or
acilities hepigrevent. Missing for a coloris headed wounds. Coro DRGANISHS (Include to wounds. Coro DRGANISHS (Include to more and to mor	endro/PPE hersil, acadio with target acadio with the copy of lab ress own to be coloning precautions or other lab re Copy and the coloning precautions or other lab re Copy and the coloning precautions of the colonic Colo	i.e., gown and glosder and a set of the set	re use for his stant organi hese patien in ID and an with any in recautions ast date(s) [c] [c] [c] [c] [c] [c] [c] [c] [c] [c	gh-contact care a sms (MOROs), ind ts in acute care s timicrobial susc nultidrug-resist (record organis of exposure if k arbapenemase)	activities for n welling devic ettings. eptibilities.; ant or other m(s), specin nown)	es or
acilities hepiprevent vitri infection or colori wheeled wounds; Con ORGANISHS (Include Wounds; Con ORGANISHS (Include Con ORGANISHS)) Patient is NOT kn organisms required to the control of the control	endro/PPE hersil, acadio with targe tact Pre-caudions to copy of lab ress own to be color of lab ress own to be co	i.e., gown and glosder defendation; years and glosder defendation; and glosder defendation sufficiently and glosder defendation; and glosder defendation of the glos	re use for his transfer for his transfer organishese patient in ID and an with any mercautions as t date(s) Cr (t)	gh-contact care a sms (MOROs), ind ts in acute care s timicrobial susc nultidrug-resist (record organis of exposure if k arbapenemase)	activities for n welling devic ettings. eptibilities.; ant or other m(s), specin nown)	es or

pertinent information can be populated directly from the EMR. However, what is most critical is ensuring the transfer information, whether on paper or electronic, is readily available to receiving facilities and completed properly.



Form Components

Facilities should include the following information in an interfacility transfer communication form (also found on the CDPH form):

- Contact information for receiving and transferring facilities
- MDRO and other communicable disease status and accompanying laboratory results
- Current Transmission-based Precautions and supporting clinical data
- Current antimicrobials including indication, start date, and planned stop date
- Medical devices
- Immunization status

Facilities may consider including the following information (not currently on the CDPH form):

- Reason for transfer
- Mental, ambulatory, and speech status at baseline and transfer
- Current medications and recent medication changes
- · Recent antimicrobials including indication, start date, and stop date
- Past medical history
- Procedures completed during stay
- Radiology, pathology, and other laboratory results
- Pending test results
- Instructions for the receiving facility



Barriers and Solutions



Who is responsible for completing the interfacility transfer form?

Though the primary responsibility lies with the transferring facility, both the transferring and the receiving facility should identify and train responsible staff and document information communicated and received. We recommend placing the interfacility transfer form as the top page in the package of documents sent with the patient.

Establishing strong working relationships within your referral network will facilitate ongoing communication and feedback. Transferring facility staff often call the accepting facility to ensure communication of patient MDRO status upon transfer.



Our facility would like to use the form, but a handwritten form is too timeconsuming.

Facilities may consider working with their information technology team to incorporate an interfacility transfer form into their EMR system that can automatically populate relevant patient information. Some California hospitals have successfully created electronic versions (see examples of hospitals below). Regardless, ensuring appropriate transfer of information should be a patient safety priority.



How can we encourage other facilities in our county to use the interfacility transfer form?

County-wide collaboratives, including those led by local health departments, can be a great forum to strategize solutions to barriers and to connect facilities. One county has mandated use of the interfacility transfer form for all patients. Facilities can also directly contact facilities with which they commonly share patients to inquire about improving the transfer process.



How can the interfacility transfer form help with our facility's antimicrobial stewardship program?

Receiving facilities often continue overly broad or prolonged antimicrobials due to uncertainty about indication, start date, planned duration, or final culture results. The interfacility transfer form includes this information, allowing receiving facilities to limit antimicrobials to an appropriate duration, follow-up on pending results, and de-escalate therapy based on culture and susceptibility results as appropriate.

See the <u>CDPH Interfacility Transfer</u>
<u>Communications Guide</u> (www.cdph.ca.go
v/Programs/ CHCQ/HAI/Pages/Interfa
cilityCommunication.aspx) for answers to
additional FAQs.



FAQs: AUR Reporting for the CMS
Promoting Interoperability Program

(www.cdc.gov/nhsn/cms/cms-faq-aur.html)



Electronic Solutions for Interfacility Communication

Using Interfacility Electronic Medical Record (EMR) Access to Improve Stewardship



Healthcare facilities can take advantage of current EMR features to access patient information from outside facilities. For example, EPIC's Care Everywhere function provides access to records at other facilities using EPIC as well as other EMR systems. Additionally, PointClickCare, a common EMR system used in many SNFs, allows many hospitals access to, at minimum, the Continuing Care Document, which includes transfer and discharge

information. To further improve clinical communication and support antimicrobial stewardship and MDRO prevention, facilities may consider establishing secure interfacility data-sharing mechanisms, particularly between SNFs and hospitals that frequently share patients. Examples include data use agreements and

granting SNF clinicians limited read-only access to the hospital's EMR system. Such data sharing can facilitate care transitions by enabling SNF clinicians limited read-only access to the hospital's EMR system. Such data sharing can facilitate care transitions by enabling SNF clinicians to easily access patient lab reports (including those not yet resulted at transfer), clinical history, and active treatment plans, thus fostering a coordinated approach to patient care.



CMS Operational Guidance for Acute Care
Hospitals to Report AUR Data (PDF)

(www.cdc.gov/nhsn/pdfs/cms/AUR_PIP_ Op-Guidance_08-2023.pdf)

Examples of Hospitals Updating Their EMR to Improve Transfers



A Sacramento Area hospital updated their EMR to automatically generate and populate the interfacility transfer form. Sacramento County mandated use of the interfacility transfer form (PDF) (dhs.saccounty.gov/PUB/Documents/ME-HealthOrder-HealthCareFacilityTransferForm.pdf).



A San Francisco Bay Area hospital updated their EMR to automate MDRO admission screening for admissions from high-risk facilities.

For guidance on incorporating these features into your EMR, please contact your information technology or EMR representative. If your hospital has automated EMR processes that support MDRO surveillance or improve patient transfer, please share with us at HAIProgram@cdph.ca.gov. Many hospitals have asked CDPH how they can use technology to limit MDRO transmission and improve patient safety, and we would like to spotlight your hospital in a future newsletter.



Examples of of Local Health Departments Facilitating Interfacility Notification of MDRO Status

Los Angeles County Department of Public Health



In June 2024, the Los Angeles County Department of Public Health (LACDPH) released an early version of the Patient Safety Information Exchange (PSIE). Developed specifically for IPC professionals in hospitals and SNFs, PSIE provides users with secure, web-based

access to patient MDRO history as reported to LACDPH. By allowing users to quickly determine whether a patient has a reported MDRO history, PSIE supports the timely implementation of appropriate Transmission-based Precautions at admission. Nearly 200 users from 100+ hospitals and SNFs have registered for PSIE access as of June 2025. Early user feedback indicates that, when admitting patients, PSIE is particularly useful for checking carbapenem-resistant Enterobacterales, carbapenemase-producing organism, and Candida auris history. A future release expected in late 2025 will enable participating healthcare facilities to

receive automated, real-time MDRO notifications. PSIE is currently available for hospitals ans SNF users in Los Angeles County and the cities of Pasadena and Long Beach. For more **information about PSIE**, please visit their website (publicheal th.lacounty.gov/acd/patientsafetyinformationexchange/)or email psie@ph.lacounty.gov.



CMS FY 2025 Inpatient PPS Final Rule (PDF)

(www.cdc.gov/nhsn/pdfs/cda/PHD I-Facility-Guidance-508.pdf)

Orange County Public Health Department



The Orange County (OC) MDRO Xchange was developed to improve communication of patients' MDRO status across healthcare settings. Within OC, the Xchange will provide staff

in hospitals and SNFs with secure access to a database of MDRO-colonized patients. The Xchange database of MDRO-colonized patients is populated by an automated feed from CDPH's CalREDIE system, which clinical laboratories currently use to report certain MDROs to public health. The Xchange launched with a pilot acute care hospital in November 2024, with plans to enroll all OC acute care hospitals and SNFs that wish to participate. For more information, please email <a href="https://example.com/hall-en-

Clinical and Laboratory Standards Institute Strengthens Recommendations for Carbapenemase Testing of Carbapenem-Resistant Enterobacterales



Per Clinical and Laboratory Standards Institute (CLSI) 2025 updated M100 guidance, most carbapenem-resistant Enterobacterales (CRE) should be tested for carbapenemase production, ideally with an assay that can differentiate specific carbapenemase types. Please see Please see CLSI M100 ED35:2025



(em100.edaptivedocs.net/Login.aspx?returl=GetDoc.aspx%3fdoc%3dCLSI%2520M100%2520ED35%3a20 25%26sbssok%3dCLSI%2520M100%2520ED35%3a2025%2520TABLE%25202A-1%26format%3dHTML% 26hl%3dcarbapenemase) Table 2A-1 for additional details and considerations. The Infectious Diseases Society of America (IDSA) also strongly encourages carbapenemase testing of CRE to help direct therapy in their 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections (www.idsociety.org/practice-guideline/amr-guidance/).

State Lab Announces New STAR-Carba Assay

As part of an ongoing effort to modernize testing methodologies for antimicrobial-resistant pathogens, the CDPH Microbial Diseases Laboratory (MDL) replaced the modified carbapenem inactivation method (mCIM) with the Bruker MBT STAR®-Carba assay. The MBT STAR-Carba assay is a MALDI-TOF-based phenotypic method that can rapidly and accurately detect carbapenemase-producing organisms (CPOs), including carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa (CRPA), and Acinetobacter baumannii (CRAB). The MBT STAR®-Carba assay will complement the existing lineup of CPO identification and testing services at CDPH MDL. For isolate submission criteria, please refer to the Expanded Carbapenemase Testing Services Frequently Asked Questions (FAQs) (www.cdph.ca.gov/Program s/cls/idld/mdl/Pages/MDL-Expanded-Carbapenemase-Testing-Services-FAQs-2025.aspx) updated February 5, 2025.



Have questions about the NHSN Antimicrobial Use and Resistance Module?

Contact NSHN at NHSN@cdc.gov or submit a ticket to <u>ServiceNow</u> (https://servicedesk.cdc.gov/nhsncsp)

CDPH HAI Antimicrobial Stewardship Program Honor Roll Gold-Level Facility Spotlights



In each newsletter, we highlight <u>CDPH Antimicrobial Stewardship Honor Roll Members</u> (www. cdph.ca.gov/ Programs/CHCQ/HAI/Pages/HonorRollMembers.aspx) that have achieved gold designation. The facilities listed below achieved, or renewed, gold status during the September 2024 deadline.

Collaborations to Improve Antimicrobial Stewardship

- Palomar Medical Center
- Providence St. Joseph Hospital
- Sutter Davis Hospital

Supporting a Less Resourced Facility

- Hoag Orthopedic Institute
- Kaiser Foundation Hospital Vacaville
- Novato Community Hospital
- Saint Johns Health Center
- AHMC Seton Medical Center

CDPH

Direct Engagement with Outpatient Partners in the Community

- Alta Bates and Summit Medical Center Campuses
- Community Memorial Hospital San Buenaventura
- Eisenhower Medical Center
- Kaiser Foundation Hospital -Oakland/Richmond
- Kaiser Foundation Hospital San Leandro
- Keck Hospital of USC
- Martin Luther King Jr. Community Hospital
- Providence St. Jude Medical Center
- · Sequoia Hospital
- St. Elizabeth Community Hospital
- Sutter Maternity and Surgery Center of Santa Cruz
- UCLA Medical Centers Ronald Reagan and Santa Monica
- USC Kenneth Norris Jr. Cancer Hospital

Explore the <u>CDPH ASP</u> <u>Honor Roll Map</u> to discover other facilities in your region and find out when your facility's designation expires.

(www.cdph.ca.gov/Programs/ CHCQ/HAI/Pages/HonorRoll_In teractiveMap.aspx)





Did you miss our <u>resource issue</u>?

<u>Issue 4 (PDF)</u> of *The ASR Update* highlighted resources for antimicrobial resistance, antimicrobial stewardship, diagnostic stewardship, regional and state laboratory testing, and updated breakpoints.

This issue is updated periodically to reflect the most recent links and resources!

(www.cdph.ca.gov/Programs/CHCQ/HAI/CDPH%20Document%20Library/AS_AR_Newsletter_Issue4_May2024.pdf)

Other Updates

Public Health Laboratory Experience with Whole Genome Sequencing of Multidrug-Resistant Organisms

- <u>Slides(PDF)(www.cdph.ca.gov/Programs/CHCQ/HAI/CDPH%20Document%20Library/PH_LabExpWithWGSofMDR0s_051425.pdf)</u>
- Recording (5/14/2025) (www.youtube.com/watch?v=o ZF_AM1Zn84)

CDC Alert | Use Only Sterile Ultrasound Gel for Percutaneous Procedures

CDC has received reports of *Paraburkholderia fungorum* bacteremia associated with the <u>use of ultrasound</u> <u>gel from multiple states during 2024–2025</u> (www.cdc.gov/healthcare-associated-infections/bulletins/outbre ak-ultrasound-gel.html). Use of non-sterile ultrasound gel for percutaneous procedures risks patient safety. CDC emphasizes the following: 1) use only single-use ultrasound gel products labeled as "sterile" for ultrasonography in preparation for or during percutaneous procedures, 2) train health care providers whoperform ultrasounds and/or ultrasound-associated procedures in the appropriate use of ultrasound gel



products, and 3) consider ultrasound gel products with a label claim of "bacteriostatic" or "preservative" without a specific indication of sterility as non-sterile for clinical purposes.

For additional information and further recommendations, please see <u>CDC's Alert</u> (www.cdc.gov/healthcare-associated-infections/bulletins/outbreak-ultrasound-gel.html).

CDC HAI/AR Program Publications

- The Journal of the American Dental Association: <u>Outpatient antibiotic prescribing by general dentists in</u> the United States from 2018 through 2022 (3/6/2025)(pubmed.ncbi.nlm.nih.gov/40047737/)
- Antimicrobial Stewardship & Healthcare Epidemiology: <u>Implementation of core elements of antibiotic stewardship in long-term care facilities—National Healthcare Safety Network, 2019–2022 (3/24/2025)</u> (pmc.ncbi.nlm.nih.gov/articles/PMC11951231/)

Upcoming



CDPH ASP Honor Roll

- Deadlines: March 1st and September 1st; as a reminder, designations are for 3 years.
- Visit the <u>ASP Honor Roll webpage</u> (www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/Honor_Roll. aspx) for more information about application requirements.



Stay Connected with CDPH

CDPH HAI Websites

Visit CDPH webpages for more information and resources.

- CDPH HAI Program (www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/HAI/ProgramHome.aspx)
- CDPH <u>Antimicrobial Stewardship</u> (www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/AntimicrobialStew ardshipLandingPage.aspx)
- CDPH <u>Antimicrobial Resistance</u> (www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/AntimicrobialResistanceLandingPage.aspx)

CDPH HAI Newsletters

Subscribe to our <u>HAI Program newsletters</u> (cdph-marketing.powerappsportals.com/HAI/HAI-Registration/) to receive updates on our program's initiatives and educational opportunities.

CDPH Listserv

To stay connected with all things antimicrobial stewardship at CDPH, join the <u>California Antimicrobial Stewardship Collaborative Network (ASCN)</u> (www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/ASCN.aspx).



HAI Program LinkedIn

(www.linkedin.com/in/hai-healthcare-associated-infections-program-7ba7ab178)

HAIProgram@cdph.ca.gov